Tianjin Chase Sun Pharmaceutical Co Ltd Total Liabilities
Tianjin Chase Sun Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has total liabilities worth CN¥1.65 Billion CNY (≈ $241.01 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300026 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
Total liabilities of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024. This chart illustrates how Tianjin Chase Sun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Tianjin Chase Sun Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Tianjin Chase Sun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Chase Sun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Construction Investment Group Co Ltd
SHE:002761
|
China | CN¥107.64 Billion |
|
Shenzhen Injoinic Technology Co. Ltd. A
SHG:688209
|
China | CN¥215.38 Million |
|
TriMas Corporation
NASDAQ:TRS
|
USA | $803.04 Million |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs1.96 Billion |
|
Lotte Chemical Corp
KO:011170
|
Korea | ₩13.78 Trillion |
|
Vistance Networks, Inc.
NASDAQ:VISN
|
USA | $991.00 Million |
|
Orezone Gold Corporation
AU:ORE
|
Australia | AU$742.92 Million |
|
Hugel Inc
KQ:145020
|
Korea | ₩104.15 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Tianjin Chase Sun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300026 total assets.
Liquidity & Leverage Metrics
Tianjin Chase Sun Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Tianjin Chase Sun Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Chase Sun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total liabilities of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.37 Billion ≈ $346.30 Million |
-20.24% |
| 2023-12-31 | CN¥2.97 Billion ≈ $434.20 Million |
-28.80% |
| 2022-12-31 | CN¥4.17 Billion ≈ $609.88 Million |
+14.03% |
| 2021-12-31 | CN¥3.65 Billion ≈ $534.83 Million |
+31.11% |
| 2020-12-31 | CN¥2.79 Billion ≈ $407.94 Million |
+105.55% |
| 2019-12-31 | CN¥1.36 Billion ≈ $198.46 Million |
+49.43% |
| 2018-12-31 | CN¥907.61 Million ≈ $132.81 Million |
-1.31% |
| 2017-12-31 | CN¥919.62 Million ≈ $134.57 Million |
-26.00% |
| 2016-12-31 | CN¥1.24 Billion ≈ $181.84 Million |
+5.07% |
| 2015-12-31 | CN¥1.18 Billion ≈ $173.07 Million |
+72.69% |
| 2014-12-31 | CN¥684.85 Million ≈ $100.22 Million |
+32.62% |
| 2013-12-31 | CN¥516.40 Million ≈ $75.57 Million |
+24.38% |
| 2012-12-31 | CN¥415.19 Million ≈ $60.76 Million |
+16.15% |
| 2011-12-31 | CN¥357.47 Million ≈ $52.31 Million |
+96.26% |
| 2010-12-31 | CN¥182.14 Million ≈ $26.65 Million |
+35.02% |
| 2009-12-31 | CN¥134.90 Million ≈ $19.74 Million |
+47.22% |
| 2008-12-31 | CN¥91.63 Million ≈ $13.41 Million |
-19.47% |
| 2007-12-31 | CN¥113.79 Million ≈ $16.65 Million |
+34.91% |
| 2006-12-31 | CN¥84.34 Million ≈ $12.34 Million |
-- |
About Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves th… Read more